Andrew Owen is a Professor in the Department of Molecular and Clinical Pharmacology at the University of Liverpool. He is also affiliated to the MRC Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, and a member of the steering committee for the Academy of Pharmaceutical Sciences Nanomedicines Focus Group. His research focuses on the mechanisms that underpin interpatient variability in pharmacokinetics and pharmacodynamics for drugs used in infectious diseases. In recent years a major emphasis has been to employ knowledge of these mechanisms to accelerate translation of nanomedicine candidates to clinical applications. Research funding has been secured from the US National Institutes for Health, the UK Medical Research Council, the European Commission, the UK Engineering and Physical Sciences Research Council, the British Society for Antimicrobial Chemotherapy and the Clinton Health Access Initiative. Prof. Owen has published over 140 original research papers, review manuscripts and book chapters, and is co-inventor of patents relating to the application of nanotechnology to drug delivery. He is also a Co-Editor in Chief for the Journal of Interdisciplinary Nanomedicine (www.JOINjournal.com).
Conflict of Interest: Dr. Owen has reported having potential financial conflicts of interest within the past 12 months, or anticipated within the coming 12 months, with the following entities: Merck; GSK; Janssen; ViiV Healthcare